Issued Patents All Time
Showing 1–25 of 33 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12383601 | Chimeric antigen receptors and uses thereof | Aida Abujoub, John W. Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu +20 more | 2025-08-12 |
| 12037583 | Compositions and methods for immunooncology | Ming-Wei Chen, Melissa Deck, Craig Stephen MICKANIN, Reynald Michael Lescarbeau, Celeste Richardson +2 more | 2024-07-16 |
| 11998593 | Combination vaccine devices and methods of killing cancer cells | Omar Abdel-Rahman Ali, David J. Mooney | 2024-06-04 |
| 11851472 | NKG2D-IG fusion protein for cancer immunotherapy | Ryan Sullivan, Matthew Vanneman | 2023-12-26 |
| 11624093 | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response | Kwok-Kin Wong, Chunxiao Xu, Christine F. Brainson, Carla F. Kim, Peter Hammerman | 2023-04-11 |
| 11597934 | Methods and compositions for reducing immunosuppression by tumor cells | Kai W. Wucherpfennig, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey Cantor +1 more | 2023-03-07 |
| 11382905 | Immunomodulation by IAP inhibitors | Leigh Zawel, Christopher Sean Straub, Brant G. Firestone, Michael Dougan | 2022-07-12 |
| 10876120 | Methods and compositions for reducing immunosupression by tumor cells | Kai W. Wucherpfennig, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey Cantor +1 more | 2020-12-29 |
| 10865232 | NKG2D-IG fusion protein for cancer immunotherapy | Ryan Sullivan, Matthew Vanneman | 2020-12-15 |
| 10865233 | NKG2D-fc for immunotherapy | Matthew Vanneman, Gordon J. Freeman | 2020-12-15 |
| 10851165 | Antibody molecules to PD-L1 and methods of treating cancer | Gordon J. Freeman, Arlene H. Sharpe, Gerhard Frey, Hwai Wen Chang, Jennifer Marie Mataraza | 2020-12-01 |
| 10793633 | Therapeutic peptides | Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May, Jr., F. Stephen Hodi, Christopher Harvey | 2020-10-06 |
| 10786491 | Immunomodulation by IAP inhibitors | Leigh Zawel, Christopher Sean Straub, Brant G. Firestone, Michael Dougan | 2020-09-29 |
| 10745483 | Therapeutic peptides | Kai W. Wucherpfennig, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey | 2020-08-18 |
| 10682400 | Combination vaccine devices and methods of killing cancer cells | Omar Abdel-Rahman Ali, David J. Mooney | 2020-06-16 |
| 10662247 | Compositions and methods of use for augmented immune response and cancer therapy | Jennifer Brogdon, Daniela Cipolletta, Deborah A. Knee, Fei Wang | 2020-05-26 |
| 10568949 | Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devices | Omar Abdel-Rahman Ali, David J. Mooney | 2020-02-25 |
| 10328133 | Continuous cell programming devices | David J. Mooney, Omar Abdel-Rahman Ali | 2019-06-25 |
| 10279021 | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | Kai W. Wucherpfennig, Christopher Harvey, F. Stephen Hodi | 2019-05-07 |
| 10258677 | Continuous cell programming devices | David J. Mooney, Omar Abdel-Rahman Ali | 2019-04-16 |
| 10226476 | Method of attenuating reactions to skin irritants | S. Brian Wilson, Silke Gillessen | 2019-03-12 |
| 10106611 | Antibodies that bind to MHC class I polypeptide-related sequence A | Kai W. Wucherpfennig, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey | 2018-10-23 |
| 9988452 | Antibody molecules to PD-L1 and uses thereof | Gordon J. Freeman, Arlene H. Sharpe, Gerhard Frey, Hwai Wen Chang, Jennifer Marie Mataraza | 2018-06-05 |
| 9944931 | Methods and compositions for reducing immunosupression by tumor cells | Kai W. Wucherpfennig, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey Cantor +1 more | 2018-04-17 |
| 9821045 | Controlled delivery of TLR3 agonists in structural polymeric devices | Omar Abdel-Rahman Ali, David J. Mooney | 2017-11-21 |